Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BLU-701 + Carboplatin + Pemetrexed Disodium|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BLU-701||BLU701|BLU 701||EGFR Inhibitor 4th gen 3||BLU-701 is a reversible EGFR inhibitor that blocks the activity of mutant forms of EGFR, including C797S, while sparing wild-type EGFR, which results in reduced downstream signaling and potentially leads to decreased tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1262).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Pemetrexed Disodium||Alimta||LY231514||Chemotherapy - Antimetabolite 14||Alimta (Pemetrexed Disodium) is an antifolate, which inhibits thymidylate synthase (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05153408||Phase Ib/II||BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium||(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC||Recruiting||USA||0|